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 309 
ABSTRACT  310 
Reduced cardiac vagal control reflected in low heart rate variability (HRV) is associated with 311 
greater risks for cardiac morbidity and mortality. In two-stage meta-analyses of genome-wide 312 
association studies for three HRV traits in up to 53,174 individuals of European ancestry we detect 313 
17 genome-wide significant SNPs in eight loci. HRV SNPs tag non-synonymous SNPs (in 314 
NDUFA11 and KIAA1755), eQTLs (influencing GNG11, RGS6, and NEO1), or are located in genes 315 
preferentially expressed in the sinoatrial node (GNG11, RGS6, and HCN4). Genetic risk scores 316 
account for 0.9 to 2.6% of the HRV variance. Significant genetic correlation is found for HRV with 317 
heart rate (-0.74 < rg < -0.55) and blood pressure (-0.35 < rg < -0.20). These findings provide 318 
clinically relevant biological insight into heritable variation in vagal heart rhythm regulation, with a 319 
key role for genetic variants (GNG11, RGS6) that influence G-protein heterotrimer action in GIRK-320 
channel induced pacemaker membrane hyperpolarization. 321 
14 
 
  322 
15 
 
Heart rate variability (HRV) is a physiological variation in cardiac cycle duration. When measured 323 
under supine or sitting conditions, resting HRV is most prominently centered around the frequency 324 
of respiration (~0.25 Hz) and the intrinsic blood pressure rhythm (~0.1 Hz). This reflects 325 
modulation of tonic activity in the cardiac vagal nerves originating in cortical and subcortical nuclei 326 
1
 by oscillatory input at the brainstem level from cardiorespiratory coupling, lung stretch-reflexes, 327 
and arterial chemo- and baroreceptors 
1, 2
. This vagal gating gives rise to oscillatory vagal effects on 328 
the pacemaker potentials in the sinoatrial node that scales with the tonic activity in the vagal nerves 329 
and provides a source of beat-to-beat variation in heart rate. Due to its good reproducibility 
3
 and 330 
ease of measurement, HRV is a widely used non-invasive research and clinical tool to quantify the 331 
degree of vagal control of heart rate 
4
.  332 
 Loss of cardiac vagal control as indexed by low HRV is associated with mortality in patients 333 
with cardiovascular disease 
5
. Animal research further supports a role for cardiac vagal activity in 334 
preventing sudden death and ventricular fibrillation 
6
. In addition, hypertension 
7
, end-stage renal 335 
disease 
8
 and diabetes 
9
 are all associated with low HRV. Although the above associations may 336 
partly reflect impaired cardiac vagal control caused by these diseases, lowered HRV does not 337 
simply indicate disease severity as it also predicts all-cause mortality 
10
 and cardiac morbidity and 338 
mortality 
11, 12
 in apparently healthy individuals.  339 
Large inter-individual differences in HRV exist in the basal resting state. Family and twin 340 
studies have uniformly confirmed a substantial genetic contribution to resting HRV with 341 
heritability estimates between 25% and 71% 
13
.  Candidate gene studies based on current 342 
knowledge of parasympathetic nervous system biology have not yielded results that hold up in 343 
replication
14
. To improve our understanding of the genetic basis of HRV, we performed a two-stage 344 
meta-analysis of genome-wide association studies (GWAS) in up to 53,174 individuals of 345 
European ancestry on three HRV traits (the standard deviation of the normal-to-normal inter beat 346 
intervals [SDNN], the root mean square of the successive differences of inter beat intervals 347 
16 
 
[RMSSD], and the peak-valley respiratory sinus arrhythmia or high frequency power 348 
[pvRSA/HF]). These HRV traits were measured during resting, basal recordings ranging in length 349 
from ultrashort 10-s electrocardiograms (ECGs) to up to 90 minutes of sitting or from 2-12 hours 350 
of daytime recording. Relevance of the identified loci for other ethnicities was examined in data 351 
from 11,234 Hispanic/Latino and 6,899 African-American individuals. In silico post-GWAS 352 
analyses were performed to test for association with cardiac disease risk factors and disease 353 
outcomes and to provide insights into the biological mechanisms by which the identified loci 354 
influence cardiac vagal control and its effect on HRV.  355 
We detect 17 SNPs in eight loci harboring several genes preferentially expressed in the 356 
sinoatrial node and significant negative genetic correlations of HRV with heart rate and blood 357 
pressure. These findings provide clinically relevant biological insight into heritable variation in 358 
vagal heart rhythm regulation, with a key role for genetic variants in proteins (RGS6, GNG11) 359 
known to influence G-protein heterotrimer action in GIRK-channel induced pacemaker membrane 360 
hyperpolarization. 361 
 362 
RESULTS 363 
New loci associated with HRV 364 
We meta-analyzed results from GWAS on three HRV traits (see Methods for details) performed by 365 
20 cohorts of European ancestry in up to 28,700 individuals (Figure 1; Supplementary Fig. 1-3; 366 
Supplementary Tables 1-4). Using a significance threshold of 1x10
-6
, 23 single nucleotide 367 
polymorphism (SNPs) in 14 loci that were associated with one or more of these HRV traits were 368 
taken forward for wet lab genotyping or in silico replication in 11 cohorts including up to 24,474 369 
additional individuals of European ancestry, followed by a second stage meta-analysis 370 
(Supplementary Data 1).  371 
17 
 
After stage 2, we identified 17 lead SNPs (11 independent) in eight loci (Table 1) that 372 
reached genome-wide significance (p < 5x10
-8
). The loci on chromosomes 14 and 15 contained 373 
three and two independent signals, respectively (Supplementary Fig. 3). Conditional analysis 374 
confirmed the presence of independently associated variants in these loci (Supplementary Table 5). 375 
In total, nine independently associated SNPs in seven loci were detected for SDNN, nine 376 
independently associated SNPs in eight loci for RMSSD, and five independently associated SNPs in 377 
five loci for pvRSA/HF. Many of the SNPs were associated with at least two of the HRV traits 378 
(Supplementary Data 1). In four loci, the lead SNPs differed between traits but were in linkage 379 
disequilibrium (LD) with each other (0.24<r
2
<0.90) (Table 1). Forest plots show little heterogeneity 380 
in the genetic associations across the entire set of cohorts for all SNPs (Supplementary Fig. 4). Sex-381 
stratified analyses did not show differences in SNP effects between men and women for the 382 
genome-wide associated loci (Supplementary Table 6). Separately meta-analyzing across cohorts 383 
with short laboratory rest recordings versus longer term ambulatory recordings did not suggest 384 
sensitivity of the results to these different recording methods (Supplementary Table 7). Results of 385 
VEGAS gene-based analyses corroborated those of the SNP-based analyses (Supplementary Note 386 
1). 387 
 388 
Variance explained  389 
Weighted genetic risk scores based on the independent SNPs that reached genome-wide 390 
significance after the second stage meta-analysis were computed for the three HRV traits and used 391 
to predict RMSSD, SDNN, and pvRSA/HF in adults from the Lifelines (n=12,101) and NESDA 392 
(n=2,218) cohorts, adolescents from the TRAILS-Pop cohort (n=1,191), and children from the 393 
ABCD cohort (n=1,094) (Table 2). The multi-SNP genetic risk scores were all significantly 394 
associated with HRV and the percentages of variance explained for the corresponding traits were 395 
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1.0-1.4% for SDNN, 1.1-2.4% for RMSSD, and 0.9-2.6% for pvRSA/HF. Cross-trait explained 396 
variances of genetic risk scores were close to those for the corresponding trait.  397 
To test the contribution of SNPs that did not reach genome-wide significance, we performed 398 
polygenic risk score analyses using increasingly more lenient significance thresholds and 399 
determined the percentages of explained HRV in the same four cohorts (Supplementary Fig. 5; 400 
Table 3). Maximal variance explained by the polygenic risk score was 0.8-1.4% for SDNN, 0.9-401 
2.3% for RMSSD, and 0.9-2.3% for pvRSA/HF. This was reached at relatively small numbers of 402 
SNPs (≤71) with additional SNPs adding more noise than signal.  403 
The total variance explained by common SNPs (SNP-based heritability) estimated by 404 
Genomic Restricted Maximum Likelihood or LD score regression analysis varied between 10.8 and 405 
13.2%, with only small differences in estimates across methods and HRV traits (Supplementary 406 
Note 2). 407 
 408 
Generalization to other ethnicities 409 
In data from up to 11,234 Hispanic/Latino individuals, five SNPs in five of the eight loci identified 410 
for RMSSD, seven SNPs in six of the seven loci for SDNN, and three SNPs in three of the five loci 411 
for pvRSA/HF showed a statistically significant association that was consistent in direction with the 412 
association in individuals of European ancestry (Table 4). In data from 6,899 African-Americans, 413 
four SNPs from four of the eight loci were associated with RMSSD, three SNPs in three of the 414 
seven loci with SDNN, and none with pvRSA/HF. In the combined meta-analysis in a maximum of 415 
71,675 participants from all ethnicities, one SNP (rs6123471 on chromosome 20) was no longer 416 
significant (Table 4). 417 
 418 
Correcting HRV for heart rate  419 
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The strong inverse association between HRV and heart rate reflects the well-established 420 
simultaneous biological effect of cardiac vagal activity on heart rate 
15
 and HRV 
16
, but it also 421 
expresses a mathematical dependency of the variance in inter beat interval (IBI) on the mean IBI 422 
that is unrelated to the underlying biology. We conducted three analyses to test whether the 423 
association of the HRV SNPs was robust to correction of the HRV traits for heart rate 424 
(Supplementary Table 8). First, we used a recently developed analytical technique
17
 to obtain the 425 
meta-analysis for the coefficient of variation of SDNN and RMMSD from the summary statistics of 426 
the HRV and resting heart rate meta-analyses
18
. The coefficient of variation detects the amount of 427 
IBI variability relative to the mean IBI of each subject, and deals with the proportionality-based 428 
dependence of HRV on heart rate
19
. Second, we established the effect of the 17 HRV SNPs on the 429 
coefficients of variation for SDNN and RMSSD in the Lifelines, NESDA and TRAILS-Pop 430 
cohorts, and meta-analyzed the results. Third, we use a mediation analysis in these same cohorts to 431 
see how much of the SNP effects on the three HRV measures was mediated by heart rate. In all 432 
three analyses, we find some attenuation of the HRV SNP associations. The average mediation of 433 
the association by heart rate was ~28%. However, the correction for heart rate left most of the HRV 434 
SNP associations intact, particularly in the first analysis that used the full discovery sample.  435 
 436 
Association of the HRV SNPs with resting heart rate  437 
Because the HRV traits reflect cardiac vagal activity, we expected the HRV SNPs to have an effect 438 
on resting heart rate. We performed a lookup of the 17 HRV SNPs in a GWAS meta-analysis on 439 
resting heart rate in 85,787 individuals 
18
. Out of the 17 HRV lead SNPs, 11 were associated with 440 
heart rate after correcting for multiple testing (Supplementary Table 9). All effects were in the 441 
expected direction such that the HRV decreasing allele was associated with higher heart rate 442 
(Supplementary Fig. 6). Six of the HRV SNPs were not significantly associated with heart rate, 443 
including our top hit on chromosome 19 (rs12974991 in NDUFA11: p RMSSD = 4.6x10
-46
; p heart 444 
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rate = 0.18). Analysis of summary statistics of the HRV and heart rate meta-analyses as 445 
implemented in the gtx R package showed that multi-SNP genetic risk scores for HRV were 446 
significantly associated with heart rate (Supplementary Table 11, panel a). 447 
Additionally, genetic risk scores based on the independent genome-wide significant HRV 448 
SNPs from the combined stage 1 and 2 meta-analysis were tested for association with heart rate in 449 
the Lifelines, NESDA, TRAILS-Pop and ABCD cohorts (Supplementary Table 9, panel b). The 450 
three multi-SNP risk scores of the HRV traits explained a small, but mostly significant percentage 451 
of variance in heart rate (0.09-1.13%). Polygenic risk score analysis showed that adding HRV SNPs 452 
below the genome-wide significance threshold did not further increase the variance explained in 453 
heart rate (Supplementary Fig. 5; Supplementary Table 9, panel c).  454 
The reverse question, whether SNPs with effects on heart rate are associated with HRV, was 455 
also investigated. The 21 heart rate SNPs identified by the GWAS meta-analysis on heart rate
18
 456 
explained between 0.2 and 0.9% of the variance in the three HRV traits (Supplementary Notes, 457 
Supplementary Table 10).  458 
 459 
Association with cardiometabolic traits and diseases 460 
In addition to heart rate we examined the association of the 17 HRV-associated SNPs with other 461 
confirmed risk factors for cardiac, metabolic and renal disease traits and endpoints using data from 462 
large-scale GWAS meta-analyses (Supplementary Table 11). Multi-SNP risk scores were computed 463 
based on our 17 top SNPs and we tested their association with the outcomes.  464 
 No effects of risk scores using the 17 HRV SNPs were observed for systolic or diastolic 465 
blood pressure, body mass index, renal function, heart failure, sudden cardiac death, coronary artery 466 
disease, atrial fibrillation, or type 2 diabetes. Only for atrial fibrillation we observed individually 467 
significant SNPs. These two highly significant SNPs (rs10842383 near LINC00477, p= 3.45x10
-7
 468 
and rs2680344 in HCN4, p=4.34x10
-7
 (Supplementary Table 12) had large opposite effects on atrial 469 
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fibrillation, while both decreased HRV. In addition to these lookups that were restricted to genome-470 
wide significant SNPs, we employed bivariate LD score regression
20
 that uses the full GWAS 471 
summary statistics of the HRV and cardiometabolic traits and diseases to compute genetic 472 
correlations. The genetic correlations systematically pointed to an overlap in the genetic variants 473 
causing low HRV and increased risk for disease (i.e., negative correlations with systolic and 474 
diastolic blood pressure, coronary artery disease, heart failure, sudden cardiac death, BMI, and type 475 
2 diabetes) compatible with clinical relevance of the HRV SNPs identified, although significance 476 
was reached only for systolic and diastolic blood pressure after correction for number of outcomes 477 
tested (Supplementary Table 11). 478 
 479 
Potential functional impact of the HRV variants 480 
To identify functional variants tagged by the 17 HRV SNPs, we performed various post-GWAS 481 
annotation (Supplementary Fig. 7). In silico annotation (Supplementary Data 2) showed that the 482 
lead SNP for SDNN on chromosome 19 was a non-synonymous SNP (rs12980262 in NDUFA11) 483 
and that the lead SNPs for RMSSD (rs12974991) and pvRSA/HF (rs12974440) were in perfect LD 484 
with this SNP (Table 1; Supplementary Data 2). SNP rs129080262 was characterized as deleterious, 485 
with a SIFT score of 0.01 and a PolyPhen score of 0.753 indicating a possibly damaging effect. 486 
Functional variant analyses using RegulomeDB confirmed that rs12980262 and rs12974440 in 487 
NDUFA11 on chromosome 19 likely have functional consequences (Supplementary Table 13) by 488 
binding to transcription factors or influencing the chromatin state. SNP rs6123471 in the locus on 489 
chromosome 20 was in high LD with two non-synonymous SNPs in the KIAA1755 gene 490 
(rs3746471 [r
2
=0.94] and rs760998 [r
2
=0.55]) that are predicted to yield tolerated, benign amino 491 
acid changes (Supplementary Data 2). 492 
We examined if the 17 HRV SNPs were expression quantitative trait loci (eQTLs) in a large 493 
whole-blood database. Four of the HRV SNPs were significantly (false discovery rate <5%) 494 
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associated with gene expression in blood (Supplementary Table 14): rs1812835 with expression of 495 
NEO1, rs4899412 with expression of RGS6, and rs180238 and rs4262 with expression of GNG11. 496 
These four SNPs were all in strong LD with the top eQTL SNPs for these genes (r
2
>0.70) and lost 497 
significance after conditioning on the corresponding top eQTL. The eQTLs for NEO1 and RGS6 498 
were replicated in at least one other whole blood eQTL study (Supplementary Table 14). The eQTL 499 
for GNG11 was replicated in the medulla (p=2.8x10
-4
) and the anterior tibialis artery (p=8.1x10
-9
). 500 
None of the 17 SNPs reached significance in a smaller heart eQTL database. 501 
Nine of the 17 HRV SNPs were in high LD (r
2
>0.70) with SNPs associated with 502 
methylation level of one or multiple CpG sites (methylation quantitative trait loci [mQTLs]) in 503 
whole blood (Supplementary Table 15). Two of the HRV SNPs that were eQTLs also influenced 504 
methylation of the same gene in whole blood, strongly suggestive of a regulatory function for those 505 
SNPs. eQTL rs1812835 in NEO1 was associated with methylation level of cg11357013, 506 
cg19281068, cg11552023 and cg17150474. eQTL rs4262 was associated with methylation level of 507 
cg08038054 and cg06439941 in GNG11. The other two eQTLs SNPs did not achieve genome-wide 508 
significance level for an association with methylation, but eQTL rs4899412 in RGS6 was in high 509 
LD with a proxy SNP (rs2238280) that was associated with methylation level of cg19493789, 510 
which is located in a CpG island shelf near RGS6.  511 
Five other HRV SNPs were (in high LD with) mQTLs but were not themselves eQTLs. For 512 
example, HRV SNPs rs12974991, rs12974440, and rs12980262 (chromosome 19) were associated 513 
with methylation level of multiple CpG sites (cg22854549, cg03715305, and cg19211619) located 514 
in or nearby NDUFA11, but were not associated with expression level of NDUFA11 in whole 515 
blood. Such mQTLs may well exert a regulatory effect on NDUFA11 in other tissues. DEPICT 516 
tissue enrichment analysis (Supplementary Data 3; Supplementary Table 16, Supplementary Fig. 8) 517 
showed NDUFA11 expression was weak in blood, but enriched in heart, sensory, and endocrine 518 
tissues. 519 
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 520 
DISCUSSION  521 
This meta-analysis of GWAS for HRV yielded 17 lead SNPs (11 independent) in eight loci that 522 
were genome-wide significantly associated, six of which generalized to individuals of African-523 
American and Hispanic/Latino ethnicity. Various ways that correct HRV for its mathematical 524 
dependency on resting heart rate attenuated the SNP effects, but largely left the associations intact. 525 
Together, the hits in the eight loci explained 0.9-2.6% of the variance in resting HRV in four 526 
independent cohorts of European ancestry.  Details of known biological functions of the genes 527 
closest to these loci are given in the Supplementary Note 6.  528 
 We noted a strong enrichment of our HRV loci in a previously conducted meta-analysis of 529 
GWAS for resting heart rate 
18
, a known risk factor for cardiac morbidity and mortality
21, 22
. SNPs 530 
in five of the 21 resting heart rate loci (i.e. LINC00477 (C12orf67), SYT10, GNG11, HCN4, and 531 
KIAA1755) were associated with HRV at genome-wide significance level and six more attained 532 
nominal significance, with associations always in the expected direction. Genetic risk scores for 533 
HRV traits were also significantly associated with heart rate and LD score regression confirmed that 534 
the allelic variants that decrease HRV in parallel increase heart rate. This suggests to us that part of 535 
the HRV SNPs exert their effect on heart rate through oscillatory modulation of pacemaker activity 536 
by the vagal nerves.  537 
 Supplementary Figure 9 depicts the two routes by which acetylcholine released by the vagal 538 
nerves in the sinoatrial node is known to influence heart rate, both of which are supported by our 539 
results in GNG11, RGS6, and HCN4. By binding the muscarinic type 2 receptor (M2R) and 540 
dissociating the G protein heterotrimer (Gαβγ) into a Gαi/o subunit and a Gβγ component, 541 
acetylcholine inhibits the ongoing depolarization of the pacemaker cells by β1/β2-adenylatecyclase 542 
activation of funny (If) channels and calcium channels 
23
. In parallel, it acts to actively 543 
hyperpolarize the pacemaker cells by activation of the GIRK1/4 channel. Each route accounts for 544 
24 
 
about half of the tonic decrease in heart rate upon vagal stimulation 
23
, but the response time for 545 
M2R-GIRK effects on the sinus rate is much shorter than for the M2R-HCN2/4 or the β1/β2-546 
adenylatecyclase signaling pathways. Only signaling through the Gβγ component is fast enough 547 
(~0.3s) to rapidly track changes in vagal outflow to the sinoatrial node, e.g. as they occur within the 548 
duration of a single respiration (~4.5s), whereas signaling through the α subunit is too slow (>3s) to 549 
track such phasic changes in acetylcholine release 
1, 24
. GIRK signaling, therefore, accounts for most 550 
of HRV due to the phasic oscillation in vagal activity 
24
, but it accounts for only half of the tonic 551 
vagal effects on heart rate.  552 
 The above leads to HRV only partially capturing the vagal effects on heart rate. Additional 553 
reasons for the imperfect relation between HRV and vagal effects on heart rate 
1, 2
 are individual 554 
differences in: (i) resting respiration rate and depth; (ii) the amplitude of the intrinsic 0.1 Hz 555 
oscillations related to both vagal and sympathetic blood pressure regulation through the baroreflex 556 
loops; (iii) mechanotransduction or intracellular pathways stimulated by sinoatrial stretch , or (iv) 557 
the efficiency of the actual vagal gating process. These processes can have a strong impact on HRV, 558 
but less so on mean heart rate. We found six SNPs in four loci, including our top hit (rs12974991 in 559 
NDUFA11), that may act on the individual differences in these processes as they had no discernible 560 
effect on heart rate, in spite of their significant impact on HRV.  561 
 The genome-wide significant SNPs in GNG11, RGS6, and NEO1 were eQTLs and in strong 562 
LD with the top mQTLs and eQTLs for the corresponding genes. Two of these (GNG11, RGS6) 563 
readily provide a biological hypothesis to account for the associations detected in the meta-analysis. 564 
The C alleles of rs4262 and rs180238 of GNG11 coding for the γ11 subunit of the heterotrimeric G-565 
protein complex Gαβγ cause decreased expression of this subunit and were associated with lower 566 
HRV. The effects of the GNG11 eQTLs associated with lower HRV are likely to lower the 567 
availability of the γ11 subunit, thereby reducing Gβγ component-induced GIRK activation. This 568 
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potentially blunts the heart rate change in response to the oscillatory changes in cardiac vagal 569 
activity.  570 
 The regulator of heterotrimeric G-protein complex signaling, type 6 (RGS6) gene on 571 
chromosome 14 was found to be linked to three independent signals for SDNN and RMSSD. RGS6 572 
acts as a critical negative regulator of M2R signaling in the sinoatrial node of the heart rapidly 573 
terminating Gβγ signaling and thus curtailing vagal lowering of the heart rate 25, 26. The results of 574 
our meta-analysis are consistent with a role for RGS6 in decreasing HRV previously hinted at by 575 
animal experimentation
23, 27
 and a human case report 
27, 28
. The T allele of our eQTL RGS6 SNP 576 
(rs4899412) causes increased expression of RGS6. By increasing RGS6 expression, the T allele acts 577 
as a gain-of-function mutation that gives rise to a decrease in GIRK channel signaling and the 578 
observed decrease in HRV. Of note, Rgs6 
-/- 
mice, that show the expected increase in HRV, are 579 
characterized by a strong bradycardia and an increased susceptibility to AV block and atrial 580 
fibrillation which is attributed to an enhancement of GIRK-induced sinoatrial and atrioventricular 581 
node hyperpolarization by removing the negative regulation of Gβγ by RGS6.23, 26, 28  582 
 The association of the rs2680344 SNP in HCN4 is puzzling because HCN signaling does not 583 
involve the fast M2R-GIRK channels and cannot translate rapid vagal fluctuation into beat-to-beat 584 
variation in inter beat interval length, i.e. HRV. The effect of the HCN4 SNP on HRV may be 585 
secondary to its effects on the average slope of the diastolic depolarization
29
. The HCN4 protein is a 586 
key component of the If channel
30-32
 that generates the pacemaker potential by a gradual 587 
depolarization of the sinoatrial myocyte cell membrane during diastole. This 'pacemaker 588 
depolarization' phase is known to be slowed by loss-of-function mutations in the HCN4 that lead to 589 
lower heart rate 
31
 and the If is the known site of action for ivabradine and other therapeutic agents 590 
used to slow heart rate in angina patients 
32
. Of note, both ivabradine treatment 
33
 and loss-of-591 
function mutations increase the risk for atrial fibrillation 
34
. In contrast, gain-of-function mutations 592 
in the sensitivity of HCN4 for cAMP lead to higher heart rate 
30
 . This leads us to hypothesize that 593 
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the A allele of rs2680344 in HCN4 either is itself a gain-of-function mutation or tags such a 594 
mutation because it increases heart rate
18
.  595 
  High HRV is associated with lower morbidity and mortality in patients with cardiovascular 596 
disease 
5
, hypertension 
7
, end-stage renal disease 
8
, and diabetes 
9
, but also in apparently healthy 597 
individuals 
11, 12
. Using LD Score regression on meta-GWAS summary statistics from various risk 598 
factors and endpoints we find some evidence for overlap in the genetic variants causing low HRV 599 
and increased risk for disease, but significance was reached only for systolic and diastolic blood 600 
pressure after correction for multiple outcomes tested. These genetic correlations are compatible 601 
with causal effects of cardiac vagal control in the etiology of disease, but they could also be 602 
ascribed to reversed causality, where the disease process leads to lower cardiac vagal control. A 603 
strength of this study in this regard is that analyses were confined to individuals in good cardiac 604 
health, i.e. cohorts excluded patients with existing cardiovascular diseases or medication potentially 605 
impacting HRV. Because we selected individuals in good cardiac health reverse effects of disease 606 
on HRV seem less likely, although some latent pathology could have been present. However, an 607 
alternative explanation that is harder to rule out is that the genetic correlation derives from 608 
pleiotropic effects of genetic variants common to both outcomes. 609 
 Further strengths of this study were the consistency of results across the different HRV traits 610 
used to capture cardiac vagal control and the generalization of the HRV SNP effects to different 611 
ancestries, in spite of known ethnic differences in absolute resting HRV 
35
. Results also held in men 612 
and women separately and across a very large range of mean cohort ages spanning from early 613 
childhood to the late middle ages; in spite of a strong reduction in HRV values with aging 
36
. 614 
 Although effects of age and sex on HRV were taken into account in the analyses, many 615 
other factors were not. The ideal design would have corrected for the known effects of respiration 616 
depth and rate on HRV, which are independent of vagal activity 
37
. These could not be added as 617 
covariates because they were not available in most cohorts. We were liberal in excluding other 618 
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covariates like BMI, smoking and exercise in the GWAS analyses. These traits are substantially 619 
heritable themselves and adjusting for heritable covariates can bias the genome-wide association 620 
effects 
38
 or even induce non-existing associations through collider bias 
39
. Finally, instructions on 621 
pre-ECG recording behaviors like physical activity, and caffeine, alcohol, or nicotine use were not 622 
rigorously standardized across cohorts. 623 
 Direct clinical relevance of most current GWAS findings is still low and our study is no 624 
exception. Potential future clinical use of our findings hinges on the ability of our genetic variants 625 
to capture (sub)cortical, brainstem and medullary transmission of tonic vagal activity to the 626 
sinoatrial node, not just the impact of that activity on heart rate. Subcortical generation of tonic 627 
vagal activity is an important biomarker for cardiovascular health and potentially modifiable by 628 
interventions on psychosocial stress 
40
 and lifestyle habits 
41
. It can even be a transdiagnostic 629 
biomarker for psychopathology and executive cognitive functioning possibly by reflecting the 630 
integrity of prefrontal cortex functioning 
42
. Genetic markers for HRV may prove useful as 631 
instrumental variables in Mendelian Randomization 
43
 to test causal hypotheses on the effects of 632 
centrally generated vagal activity on behavioral and health outcomes.  633 
 In conclusion, this meta-analysis detects a critical role for genetic variation in Gβγ and HCN 634 
signaling in explaining individual differences in HRV. The HRV variants detected can help guide 635 
further investigations of the functional consequences and potential therapeutic implications of 636 
individual differences in sinoatrial Gβγ signaling. 637 
 638 
METHODS 639 
 640 
Study cohorts 641 
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Appropriate IRB approval and  informed consent from participants in all participating cohorts was 642 
obtained. Full information on consent procedures and details of the IRB boards are provided in the 643 
Supplementary Note 8. 644 
 645 
HRV measurement 646 
In this study we investigated three HRV traits: the standard deviation of the normal-to-normal inter 647 
beat intervals (SDNN), the root mean square of the successive differences of inter beat intervals 648 
(RMSSD), and the peak valley respiratory sinus arrhythmia (pvRSA) or high frequency power 649 
(HF). SDNN and RMSSD were derived from the inter beat interval (IBI) time series obtained from 650 
the R waves in the electrocardiogram (ECG) 
4
. HF was calculated from Wavelet or Fourier 651 
decomposition with power obtained from a high frequency band of either 0.15-0.40 Hz or 0.15-0.50 652 
Hz. A time domain measure of RSA was derived by pvRSA using a respiratory signal co-registered 653 
with the ECG. Estimates of pvRSA are obtained by subtracting the shortest IBI during heart rate 654 
acceleration in the inspiration phase from the longest IBI during heart rate deceleration in the 655 
expiration phase.  656 
HRV traits were extracted from the IBI time series preferably based on 2 to 10 minute 657 
periods of ECG in a standardized setting, at rest and in a sitting/supine position. If ambulatory data 658 
was available, we advised cohorts to extract a period of sitting still in the evening, when this proved 659 
feasible. Supplementary Table 2 lists the actual way HRV was assessed by the participating cohorts. 660 
For the cohorts analyzed in stage 2 we extended our HRV measurements to include cohorts with 661 
10s and/or 20s ECG recordings, as RMSSD and SDNN based on these ultra-short recordings have 662 
shown a good agreement with 4 to 5 min recordings 
3
. Furthermore, since IBI time series require 663 
reliable detection of the R-wave only, a three-lead ECG was considered sufficient while the use of 664 
more leads was encouraged. For pvRSA, an additional respiration signal of sufficient quality to 665 
detect beginning and end of inspiration and expiration was needed. 666 
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SDNN and RMSSD have prevailed in epidemiological studies because they are more easily 667 
assessed in large cohorts and, as noted above, can be obtained even from short ECG recordings. HF 668 
and pvRSA were available in fewer cohorts, but they better reflect the cardiorespiratory coupling that 669 
drives the oscillatory modulation of vagal effects in the sinoatrial node. In the typical resting 670 
respiratory frequency range, these time- and frequency-domain measures of RSA are much less 671 
contaminated by oscillations in cardiac sympathetic control than SDNN (and other measures of HRV 672 
that span a broader frequency range). This is due to the temporal dynamics of the sinoatrial node 673 
signaling pathway that acts as a low pass filter allowing only oscillations in vagal effects to translate 674 
into HRV, whereas for sympathetic effects or vagal effects at progressively higher respiratory 675 
frequencies the node acts as a leaky integrator causing more tonic changes in heart rate 
1
. Phasic 676 
modulation of vagal effects is therefore captured most purely by pvRSA or HF. Because pvRSA 677 
and HF are conceptually similar and highly correlated with each other (r>0.80) across a wide range 678 
of values for respiration and heart rates 
44
 we grouped the analyses on pvRSA and HF under the 679 
label pvRSA/HF. 680 
 681 
Study population 682 
Cohorts that had data on at least one of the three HRV traits and genome-wide data were invited to 683 
participate in the first (discovery) stage of the Genetic Variance in Heart Rate Variability (VgHRV) 684 
consortium. The stage 1 discovery analysis was performed in up to 28,700 individuals of European 685 
ancestry from a maximum of 20 cohorts. Independent cohorts with either genome-wide or gene-686 
centered array data or with the ability to perform wet-lab genotyping on the single nucleotide 687 
polymorphism (SNPs) taken forward from the first stage were included in the second (replication) 688 
stage. This stage included additional data from up to 24,474 individuals from 11 cohorts of 689 
European ancestry (see Supplementary Tables 1-4 for cohort descriptions and details). 690 
 691 
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Association analysis: stage 1 (discovery) 692 
The following exclusion criteria were applied a priori: (1) individuals with heart disease (e.g. 693 
angina, past myocardial infarction, left ventricular failure) and (2) individuals known to use 694 
antidepressants (particularly tricyclic antidepressants) and all anticholinergic agents (e.g. digoxin, 695 
atropine, and acetylcholinesterase inhibitors) because of the strong effects that these drugs have on 696 
HRV. Individuals reporting over the counter use of anticholinergic agents were not excluded. 697 
Imputation of SNPs was done to extend and create similar SNP databases between cohorts 698 
using different genotyping platforms. Most of the cohorts used the HapMap Phase II release 22 699 
CEU panel as reference, but later releases (e.g. release 24) or other reference datasets (e.g. 700 
1000Genomes) were also used (Supplementary Table 4). 701 
Each cohort performed linear regression analyses on all available HRV traits using an 702 
additive SNP model adjusting for age at the time of ECG recording, sex, principal components - to 703 
adjust for population stratification - and other study-specific parameters; all HRV traits were log-704 
transformed because of the skewness of their distributions. Only autosomal associations were 705 
examined. Analyses were performed for all individuals as well as for men and women separately. 706 
 707 
Stage 1 meta-analysis 708 
Prior to meta-analysis, quality control of all uploaded cohort files was performed using the 709 
QCGWAS package 
45
. In case of issues the cohorts were notified and problems were solved. Using 710 
the QCGWAS results, specific imputation quality and allele frequency thresholds were set for each 711 
cohort. 712 
An inverse-variance, fixed-effects meta-analysis was performed for RMSSD and SDNN for 713 
which SNPs of the different cohorts were merged based on rs-id. For pvRSA/HF we performed a 714 
sample size weighted meta-analysis using z-scores with METAL 
46
, since we combined results of 715 
two HRV phenotypes (pvRSA and HF) that have different units and ranges, and therefore 716 
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incomparable SNP effect sizes. To get an idea of the size of the SNP effect on pvRSA/HF, we 717 
obtained effect sizes and standard errors from an additional fixed-effect meta-analysis on the 718 
GWAS results of the (majority of) cohorts that measured HF. Results of the meta-analyses were 719 
double genomic control corrected
47
 to control for potential inflation as a result of population 720 
stratification within and between cohorts. The results included all SNPs that met the following 721 
selection criteria: (a) a minor allele frequency in the meta-analysis of >1%, and (b) present in at 722 
least one third of the cohorts. This resulted in 2,555,913 SNPs being analyzed for SDNN, 2,534,714 723 
SNPs for RMSSD, and 2,628,894 SNPs for pvRSA/HF. For each trait separately, SNPs with a p 724 
<1x10
-6
 were clumped for linkage disequilibrium (LD) using pairwise LD checking in SNAP 
48
 to 725 
ascertain independent primary and secondary signals (r
2
<0.1). A total of 23 lead SNPs in 14 loci 726 
were selected for follow-up in the second (replication) stage.  727 
 728 
Stage 2 meta-analysis 729 
Stage 2 cohorts applied the same exclusion criteria and performed the same association analysis as 730 
in the discovery stage, but analyses were restricted to the 23 lead SNPs. If a SNP was not available 731 
in a cohort, the best available proxy was used instead based on strongest LD according to the 732 
1000Genomes database. To verify homogeneity of the results in the stage 2 cohorts with those in 733 
the stage 1 cohorts, the stage 1 meta-analysis effect sizes of the 23 SNPs were correlated to the 734 
effect sizes obtained in each cohort for each of the HRV traits. If a negative correlation (r<0) was 735 
found, the cohort/trait pair was excluded from stage 2 analysis. For this reason results from one 736 
cohort for SDNN were excluded. The replication results were then meta-analyzed per trait using an 737 
inverse variance fixed-effects meta-analysis for RMSSD and SDNN and a sample size p weighted 738 
meta-analysis using z-scores in METAL
46
 for pvRSA/HF. SNPs were matched based on rs-id. Next 739 
the association results from both stages were combined in the same way. A SNP was only 740 
considered to be significantly associated to HRV if it satisfied the following criteria: 1) it had p 741 
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<1x10
-6
 in stage 1, 2) it had a one-sided p<0.05 in the stage 2 meta-analysis congruent with the 742 
direction of effect in the stage 1 meta-analysis, and 3) it had a genome-wide significant p< 5x10
-8
 /3 743 
(two-sided) in the combined meta-analysis of stage 1 and 2 results, correcting for the testing of 744 
three separate traits. 745 
 746 
Conditional analysis 747 
In the discovery stage independent SNPs were selected for follow-up based on LD clumping 748 
(r
2
<0.1). To confirm independence between these SNPs within the loci on chromosome 14 and 15 749 
we applied the conditional-and-joint analysis as implemented in the Genome-wide Complex Trait 750 
Analysis software package 
49
 to the stage 1 summary statistics of RMSSD and SDNN with the 751 
genotype data of the NESDA cohort 
50
 of 1,925 individuals as the LD reference dataset. In addition, 752 
cohort-level individual data on log-transformed RMSSD and SDNN of 12,101 individuals from the 753 
Dutch Lifelines cohort 
51
 were analyzed using linear regression analysis with age and sex as 754 
covariates conditioned on the other associated SNP(s) within the locus.  755 
 756 
Gene-based association analysis (VEGAS) 757 
We performed gene-based testing with the full set of ~2.5M HapMap SNPs from GWAS results of 758 
all three phenotypes, using VEGAS (Supplementary Table 17). This software has the advantage of 759 
accounting for LD structure and the possibility to define a range beyond the gene bounds to include 760 
promoter, 5’UTR, intronic, and 3’UTR regions into the analysis. We defined a 50kb extra window 761 
beyond the genes, considered every SNP in this window for the gene-based analysis, and ran the 762 
analyses per chromosome with up to 10
6
 permutations. A p <2.5x10
-6
 (=0.05/~20.000 genes) was 763 
considered as the threshold for significance. 764 
 765 
Variance explained 766 
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The Lifelines and NESDA cohorts were used for genetic risk score and polygenic risk score 767 
analyses in order to determine the percentage of variance explained by independent HRV SNPs that 768 
were genome-wide significant, and by SNPs meeting increasingly lenient significance thresholds, 769 
respectively. Lifelines and NESDA represent examples of a population-based cohort and a cohort 770 
ascertained on case-control status (for major depressive disorder). Both recruited adult participants. 771 
To test the stability of explained variance across the life span we repeated this analysis in two other 772 
Dutch cohorts, the adolescent TRAILS-Pop cohort 
52
 (age 10-18) and the ABCD cohort consisting 773 
of young children (age 5 to 7) 
53
.  774 
For the genetic risk score, stage 1+2 summary statistics were used for the selection of HRV 775 
SNPs. No correction was needed for ABCD as genotyping in this cohort had finished only after 776 
completion of the meta-analyses. However, the NESDA cohort had been included in both stage 1 777 
and 2, TRAILS-Pop in stage 1, and Lifelines in stage 2, so the effect sizes and standard errors of the 778 
HRV SNPs were corrected to subtract the effects of those cohorts in order to obtain independent 779 
validation cohorts 
54
. Also, only SNPs were used in the genetic risk score if they remained genome-780 
wide significant after analytically subtracting these cohort's effects from the meta-analysis. Genetic 781 
risk scores of the remaining SNPs (Lifelines: SDNN(9), RMSSD(7), pvRSA/HF(5) ; NESDA: 782 
SDNN(9), RMSSD(11), pvRSA/HF(5); TRAILS-Pop: SDNN(10), RMSSD(11), pvRSA/HF(5)) 783 
weighted by the adjusted effect size were calculated for the participants of all four cohorts and 784 
regressed on the three HRV traits (pvRSA/HF was not available in Lifelines). Explained variance 785 
was computed as the change in R
2
 from a model with and without the genetic risk score, while 786 
adjusting both for age, sex, and principal components.  787 
To compute the polygenic risk scores, the imputed genotypes were first converted to best-788 
guess genotypes. This was done regardless of the imputation quality, since it was previously shown 789 
that even low-quality SNPs might contribute to the variance explained by SNPs 
54
. The SNP set was 790 
further pruned for LD using PriorityPruner (http://prioritypruner.sourceforge.net/) to select 791 
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independent SNPs, taking the significance of the SNP in the discovery meta-analysis of each of the 792 
HRV traits into account. This provided three LD-pruned SNP sets. Polygenic risk scores were then 793 
calculated in PLINK 
55
 using significance thresholds of 5x10
-8
, 5x10
-7
, 5x10
-6
, 5x10
-5
, 5x10
-4
, 0.005, 794 
0.05, 0.5, and 1 and associated with the three HRV traits and resting heart rate in the Lifelines, 795 
NESDA, TRAILS-Pop, and ABCD cohorts. For NESDA and TRAILS-Pop pruning and polygenic 796 
risk score analysis was based on analytically corrected results, since these cohorts were part of stage 797 
1 of our study 
54
.  798 
 799 
Heritabilities and genetic correlations  800 
We applied genomic restricted maximum likelihood analysis implemented in the Genomic Complex 801 
Trait Analysis software package 
56
 in the Lifelines cohort (Supplementary Table 18) to estimate the 802 
percentages of additive phenotypic variance that can be explained by common SNPs (i.e. common 803 
SNP heritability denoted as h
2
SNP). For this analysis, SNPs from the HapMap Phase 3 project were 804 
selected to obtain a set of independent SNPs. We further used LD score regression to estimate the 805 
heritabilities of the three HRV traits and the genetic correlation among HRV traits and with heart 806 
rate 
20
 . The GWAS meta-analysis summary statistics for RMSSD, SDNN, and pvRSA/HF were 807 
obtained from stage 1 of the current study, and the GWAS meta-analysis summary statistics for 808 
heart rate from the discovery stage of a recent GWAS meta-analysis for heart rate 
18
. The LD scores 809 
required by the method were computed using 1000Genomes data of Europeans. The heritabilities of 810 
the three HRV measurements were estimated using the univariate model of this method. Cross-811 
phenotype LD score regression analysis was performed using the LDSC tool (LD SCore) to 812 
estimate genetic correlations between pairs of phenotypes 
20
. 813 
In addition, we used the Oman Family Study (OFS) 
57
 to perform univariate and bivariate 814 
analyses in five multigenerational highly inbred pedigrees to estimate the heritabilities for and the 815 
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genetic correlations between log-transformed RMSSD, SDNN, HF, and heart rate using SOLAR 816 
(v7.2.5) 
58
. 817 
 818 
Generalization to other ethnicities 819 
We further examined the generalization of loci identified after meta-analysis of stage 1 and 2 results 820 
to other ethnicities using data from 11,234 individuals of two Hispanic/Latino cohorts, and 6,899 821 
individuals from five African-American cohorts (Supplementary Tables 1-4). Stage 3 meta-analyses 822 
were performed in the same way as in stage 2 of this study to assess the effect of the HRV 823 
associated SNPs in individuals of Hispanic/Latino and African-American ancestry, in the combined 824 
set of European and Hispanic/Latino ancestry, in the combined set of European and African-825 
American ancestry, and in all three ethnicities combined. Here we applied the same criteria for 826 
significance as in stage 2 described above, i.e. a SNP was only considered to be significantly 827 
associated to HRV if: 1) it had p<1x10
-6
 in stage 1 meta-analysis in European individuals, 2) it had 828 
a one-sided p<0.05 in the new ethnicity specific meta-analysis congruent with the direction of effect 829 
in the stage 1 meta-analysis in European individuals, and 3) it had a genome-wide significant 830 
p<5x10
-8
/3 (two-sided) in the combined meta-analysis. 831 
 832 
Correcting HRV for heart rate  833 
The well-known inverse association between HRV and heart rate in part reflects a dependency of 834 
the variance in IBI on the mean IBI that is unrelated to cardiac vagal activity 
59
. That is, the slower 835 
the heart rate, the longer the IBI, and therefore, any proportionally minor beat-to-beat differences in 836 
IBI are more pronounced at slower heart rates. This occurs on top of the well-established dual effect 837 
of cardiac vagal activity that lowers heart rate and increases HRV 
15, 16
. Although these two 838 
mechanisms (biological, mean-variance dependency) are impossible to completely separate, we 839 
conducted three analyses to test whether the HRV SNPs were robust to correction for the mean IBI.  840 
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First, we corrected SDNN and RMSSD for their dependency on mean IBI by using the 841 
coefficient of variation, which is a more parsimonious solution
19
 than the logarithmic approach 842 
suggested by Monfredi et al.
29
. We obtained the summary statistics for the resting heart rate GWAS 843 
meta-analysis
18
 from: https://walker05.u.hpc.mssm.edu/ and used the GWIS procedure 
17
 to infer a 844 
GWA analysis of the coefficient of variation of the SDNN and the RMSSD. We approximated the 845 
coefficients of variation by (SDNN/X)*100% and (RMSSD/X)*100% respectively, where X equals 846 
60000/heart rate. Transformation from heart rate to IBI is required as both terms in the coefficient 847 
of variation (HRV and IBI) are in milliseconds, whereas the heart rate GWAS meta-analysis used 848 
heart rate in beats per minute. As the coefficients of variation were skewed we used a log-849 
transformation. As an example of the linear approximation by GWIS we assume that the increaser 850 
effect of 1 allele for an SDNN SNP is +0.2 with the same SNP reducing heart rate by -0.1. Given a 851 
mean SDNN of 100 and mean heart rate of 60 we can then approximate (omitting some nuances 852 
adequately explained in Nieuwboer et al.
17
) the effect of the SNP on the coefficient of variation of 853 
the SDNN as: 854 
  (
        
              
)     (
   
          
)           
We used the delta method to approximate a standard error for the effect of the SNP given that we 855 
know the standard deviations for the SNP effects on SDNN and HR, and their dependence. We 856 
obtain the dependence from analysis with LD score regression
20
. 857 
Second, we performed association analyses for our 17 top SNPs on the actual log-858 
transformed coefficients of variation of SDNN and RMSSD computed in the Lifelines, NESDA, 859 
and TRAILS-Pop cohorts and then meta-analyzed these results. Because pvRSA and HF are 860 
expressed on different scales, such a meta-analysis was not feasible for pvRSA/HF. 861 
Third, we repeated the association analysis for our 17 top SNPs on SDNN, RMSSD and 862 
pvRSA/HF in the Lifelines, NESDA, and TRAILS-Pop cohorts with and without adjusting for heart 863 
rate as a covariate and performed mediation tests with the Sobel test to assess the mediation effect 864 
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of heart rate on the HRV-SNP association. Significance of the Sobel t-value was determined using a 865 
bootstrap procedure (n=10,000 permutations). The meditation p-values of the three cohorts for 866 
SDNN and RMSSD and two for pvRSA/HF (as this was not available in Lifelines) were next meta-867 
analyzed to determine the significance of mediation and to compute the percentage of the SNP 868 
effect on HRV that was mediated through its effects on heart rate. We note that this is likely an 869 
overcorrection because the HRV SNPs are expected to influence heart rate through a common 870 
biological mechanism, i.e. changes in cardiac vagal activity. 871 
 872 
Association of the HRV SNPs with heart rate  873 
We conducted a look-up of the 17 (11 independent) HRV lead SNPs identified in this study using 874 
the results of a recent GWAS meta-analysis for heart rate 
18
. A HRV associated SNP was 875 
considered to be significantly associated with resting heart rate if the GWAS meta-analysis result 876 
for heart rate was <0.05/11=0.0045. Three separate HRV weighted multi-SNP genetic risk scores 877 
were calculated from ten (SDNN), eleven (RMSSD), and five (pvRSA/HF) HRV SNPs, 878 
respectively (based on all genome-wide significant SNPs for the respective HRV trait in the stage 879 
1+2 meta-analysis). These were tested for their effect α on resting heart rate using the gtx package 880 
in R (https://cran.r-project.org/web/packages/gtx), which approximated α by (Σω × β × seβ
−2) /(Σω2 881 
× seβ
−2
) with seα ≅ √(1/ Σω
2
 × seβ
−2), where ω is the effect of the SNP on HRV, β is the effect of the 882 
SNP on heart rate and seβ is the standard error of β. This approximation requires only single SNP 883 
association summary statistics extracted from GWAS results 
60
.The effects of the multi-SNP genetic 884 
risk scores were considered as statistically significant when the p was less than 0.0045 (correcting 885 
for 11 traits; heart rate and the 10 cardiometabolic traits described below).  886 
In addition to these lookups that were restricted to genome-wide significant SNPs, we 887 
employed LD score regression
20
 that uses the full summary statistics of the HRV and heart rate 888 
GWAS meta-analyses to compute genetic correlations. 889 
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We further examined the variance in resting heart rate explained by multi-SNP genetic risk 890 
scores (based on the lead SNPs only) and of the full polygenic risk scores for HRV in the four 891 
Dutch cohorts Lifelines, NESDA, TRAILS-Pop, and ABCD. The identical approach was used as 892 
done previously for the computation of variance explained in the HRV traits themselves. 893 
 894 
Association of heart rate SNPs with HRV 895 
We also performed reverse analyses to detect the effects of heart rate SNPs on the HRV traits. In 896 
our GWAS meta-analysis results for SDNN, RMSSD, and pvRSA/HF we performed a look-up for 897 
the 21 previously identified heart rate SNPs by Den Hoed et al.
18
. A heart rate associated SNP was 898 
considered to be significantly associated with HRV if the p was <0.05/21=0.0024. The 21 heart rate 899 
SNPs were tested in a multi-SNP risk score for their effect on the HRV traits using the gtx approach 900 
as described above. 901 
To examine the variance explained in the HRV traits by the 21 heart rate SNPs, multi-SNP 902 
genetic risk scores and polygenic risk scores based on the heart rate SNPs were computed in the 903 
Lifelines, NESDA, TRAILS-Pop, and ABCD cohorts and these were tested for association with the 904 
available HRV traits. For the multi-SNP genetic risk scores weights were either the original SNP 905 
effect sizes on heart rate (for NESDA, TRAILS-Pop, and ABCD) or corrected because of 906 
participation of the cohort in the GWAS meta-analysis (Lifelines). Only 15 of the 21 SNPs were 907 
used in the Lifelines cohort because five SNPs lost genome-wide significance after subtracting the 908 
SNP effects of the Lifelines cohort. One other SNP (rs826838) was removed because it was in LD 909 
(r
2
=0.15) in Lifelines with a more significant heart rate SNP (rs7980799). 910 
 911 
Association with cardiometabolic traits and diseases  912 
We estimated the joint effect of the HRV SNPs on cardiometabolic and renal disease traits and 913 
endpoints. The traits included were systolic and diastolic blood pressure , body mass index  and 914 
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urinary albumin excretion as well as estimated glomerular filtration rate based on creatinine . The 915 
clinical outcomes used were heart failure , coronary artery disease , atrial fibrillation , sudden 916 
cardiac death , and type 2 diabetes. The relevant consortia (Supplementary Table 11) and/or 917 
corresponding authors of the studies were contacted with the request to perform a lookup and 918 
provide summary GWAS meta-analysis results for our list of 17 SNPs.  919 
The association analyses consisted of the same three steps as used for heart rate. First, we 920 
checked the p of our HRV SNPs (or their proxies) in the cardiometabolic trait or disease GWAS 921 
meta-analysis results. Second, three separate HRV weighted genetic risk scores were calculated 922 
from eleven (RMSSD), ten (SDNN), and five (pvRSA/HF) HRV SNPs, respectively (based on all 923 
genome-wide significant SNPs for the respective HRV trait in the stage 1+2 meta-analysis). These 924 
were tested for their effect on the clinical outcomes using a regression model in the gtx package in 925 
R as described above for the association of the HRV SNPs with heart rate. The effects of the genetic 926 
risk scores were considered as statistically significant when the p was less than 0.0045 (0.05/11, 927 
correcting for heart rate and the 10 traits and diseases).  928 
In addition to these lookups that were restricted to genome-wide significant SNPs, we 929 
employed LD Score regression
20
 that uses the full GWAS summary statistics of the HRV and 930 
cardiometabolic traits and diseases to compute genetic correlations. 931 
 932 
Search for known functional SNPs (in silico annotation) 933 
We followed an in silico bioinformatics-based approach 
61
 to search and annotate SNPs in the 934 
regions surrounding the 17 identified HRV SNPs. For this purpose SNP positions were converted 935 
from National Center for Biotechnology Information (NCBI) build 36, Human Genome 18, to 936 
NCBI build 37, Human Genome 19, (GRCh37/hg19) using the NCBI Genome Remapping service 937 
tool (http://www.ncbi.nlm.nih.gov/genome/tools/remap). For ±1Mb regions surrounding the SNPs, 938 
we downloaded the according variance call format file from the 1000 Genomes Project. We used 939 
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data of 503 European ancestry individuals from 1000 Genomes Project Phase 3 (version 5.a.) to 940 
calculate LD between the HRV SNP and all other SNPs within the area. SNPs in moderate to high 941 
LD (r
2≥0.5) were subsequently selected and annotated by ANNOVAR software 62 for functionality. 942 
For all non-synonymous SNPs loss-of-function and gain-of-function was determined by using the 943 
sorting intolerant from tolerant (SIFT)  and polymorphism phenotyping (PolyPhen)  prediction 944 
scores. A SNP was categorized as deleterious if the SIFT score was ≤0.05 or the PolyPhen score 945 
was between 0.957 and 1 (probably damaging). 946 
We used RegulomeDB to integrate results from the RoadMap Epigenomics and ENCODE 947 
projects to identify variants that are likely to have functional consequences using the lead SNPs 948 
identified for the three HRV traits. We distilled information on transcription factor binding and 949 
chromatin states for SNPs that showed most evidence of being functional, i.e. for SNPs with a 950 
RegulomeDB score <4.  951 
Finally, all the HRV SNPs and those that were in high LD (r
2≥0.8) with them were looked-952 
up in the National Human Genome Research Institute GWAS catalogue to check for association 953 
with other complex traits or diseases identified in previous GWAS studies 
63
. 954 
 955 
eQTL analyses 956 
We performed expression quantitative trait locus (eQTL) analysis in whole blood in order to 957 
identify regulatory variants that were associated with the HRV SNPs using the gene-expression 958 
database from NESDA 
50
 and NTR 
64
 cohorts. The sample used for this analysis consisted of 4,896 959 
individuals of European ancestry. For complete details on the sample and the procedures, see 
65
. 960 
 eQTL effects were tested with a linear model approach using MatrixeQTL 
66
 with 961 
expression level as dependent variable and SNP genotype values as independent variable. In this 962 
study we only tested cis effects for our HRV SNPs, meaning that the probe was at a distance < 1Mb 963 
from the SNP on the genome according to GRCh37/hg19. For each probe set that displayed a 964 
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statistically significant association with at least one SNP in the cis region, we identified the most 965 
significantly associated SNP (top eQTL). Conditional eQTL analysis was carried out by first 966 
residualizing probe set expression using the corresponding top eQTL and then repeating the eQTL 967 
analysis using the residualized data. 968 
All HRV SNPs with significant results in the NESDA/NTR eQTL data were looked up in 969 
two other independent whole blood eQTL databases, eQTLs in lymphoblastoid cell lines, eQTLs in 970 
ten different brain regions, and a heart eQTL database. 971 
 972 
mQTL analyses 973 
We obtained mQTL results from a previously published study 
67
.  In short, genome-wide DNA 974 
methylation data was generated using Illumina 450k arrays for 3,841 whole blood samples. 975 
Corresponding genotype data was imputed using the Genome of the Netherlands
68
 reference panel. 976 
In order to determine the effect of nearby genetic variation on methylation levels (cis-mQTLs), we 977 
performed cis-mQTL mapping using 3,841 samples for which both genotype data and methylation 978 
data were available. To this end, we calculated the Spearman rank correlation and corresponding p-979 
value for each CpG-SNP pair. We only considered CpG-SNP pairs located no further than 250kb 980 
apart. To correct for multiple testing, we empirically controlled the false discovery rate at 5%. We 981 
compared the distribution of observed p-values to the distribution obtained from performing the 982 
analysis on permuted data. Permutation was done by shuffling the sample identifiers of one data set, 983 
breaking the link between the genotype data and the methylation data. We repeated this procedure 984 
10 times to obtain a stable distribution of p-values under the null distribution. The false discovery 985 
rate was determined by only selecting the strongest effect per CpG in both the real analysis and in 986 
the permutations. 987 
 988 
Gene prioritization using four bioinformatics approaches  989 
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Potentially causal genes for the associations identified by GWAS were identified using four 990 
previously described bioinformatics tools: ToppGene, Endeavour, MetaRanker, and DEPICT 991 
(Supplementary Table 19). To this end, we first retrieved positional coordinates for all lead SNPs 992 
according to GRCh37/hg19. These coordinates were used to extract all genes located within ±40kb 993 
of lead SNPs using the UCSC genome browser. The identified genes subsequently served as input 994 
for ToppGene and Endeavour, together with two genes with established roles in sinus node function 995 
(HCN4) and synaptic signal transmission (ACHE) that served as training genes. For MetaRanker, 996 
we first combined results of the stage 1+2 meta-analyses of GWAS for the three HRV traits, 997 
retained the association with the lowest p for lead SNPs that were identified for multiple traits, and 998 
subsequently provided SNPs, p-values, and the same two test genes (HCN4 and ACHE) as input. 999 
For DEPICT - arguably the most powerful and informative of the four methods - we used results 1000 
from the stage 1 meta-analysis for all SNPs that reached a p for association <10
-5
 as input, for each 1001 
of the three HRV outcomes separately. In order for genes to be prioritized by the combined four 1002 
approaches, they needed to be either: 1) selected by DEPICT for at least one of the three HRV 1003 
outcomes; or 2) identified by at least two of the three remaining tools (ToppGene, Endeavour and/or 1004 
MetaRanker). 1005 
 1006 
Network and functional enrichment analyses 1007 
We performed gene network and enrichment analysis using the GeneMANIA algorithm, which uses 1008 
data resources on genetic interactions, protein-protein, co-expression, shared protein domains, and 1009 
co-localization networks. To build a functional interaction network we selected genes as input for 1010 
this analysis using the following criteria: (a) genes implicated by gene prioritization using the four 1011 
bioinformatics approaches described above, (b) the genes closest to our 17 HRV SNPs, (c) genes to 1012 
which linked (r
2
 > 0.50) non-synonymous SNPs mapped, (d) genes to which other linked (r
2
 > 0.80) 1013 
SNPs mapped, (e) genes identified by VEGAS, and (f) expression probe gene names significantly 1014 
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associated with HRV eQTLs (false discovery rate <0.01). The input gene list was extended to 100 1015 
by their most strongly interacting genes and a weighted composite functional association network 1016 
was constructed 
61
. Subsequently, functional enrichment analysis of all genes of the constructed 1017 
interaction network against Gene Ontology (GO) terms was performed to find the most enriched 1018 
GO terms (Supplementary Table 20). Significantly enriched GO terms (false discovery rate <0.10) 1019 
were visualized as highlighted boxes within their corresponding GO tree depicted by the RamiGO R 1020 
package 
69
 (Supplementary Fig. 10). 1021 
 1022 
Tissue and gene-set enrichment analyses 1023 
We used DEPICT for a tissue enrichment analysis to tabulate tissues that are enriched for 1024 
expression of genes located within ±40kb of SNPs with a p<10
-5
 association with the HRV traits. 1025 
DEPICT calculates the likelihood of every known gene to be a member of, amongst others, KEGG, 1026 
GEO, or REACTOME-based gene sets (N=14,461) to create reconstituted gene sets. It then 1027 
determines which of these reconstituted gene sets are enriched for the HRV genes. A graphical 1028 
representation of DEPICT’s reconstituted gene set enrichment analysis (p<0.05 after Bonferroni 1029 
correction for examining three HRV traits) was generated using a script that is based on an affinity 1030 
propagation clustering algorithm by Frey et al. 
70
. Interactions between gene sets are considered 1031 
significant if the Pearson coefficient, which is based on the number of genes that are shared 1032 
between gene sets, is >0.3. 1033 
 1034 
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Summary statistics of the meta-analyses are available on request from the corresponding authors 1036 
after a formal data access request procedure and approval by the VgHRV consortium. 1037 
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1236 
Figure 1: Manhattan plots of the meta-analyses of stage 1 GWAS results for (a) SDNN, (b) 1237 
RMSSD, and (c) pvRSA/HF in up to 28,700 individuals of European ancestry.  1238 
Only SNPs with a minor allele frequency >1% and that were present in at least 1/3 of the sample are 1239 
plotted. Significant loci are shown in blue, suggestive ones in red. The blue horizontal line 1240 
represents the genome-wide significance threshold. Genes closest to the lead SNPs are indicated for 1241 
the loci that were genome-wide significantly associated with the trait after the stage 1+2 combined 1242 
meta-analysis. 1243 
 1244 
  1245 
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Table 1: Stage 1+2 combined meta-analysis results for SDNN, RMSSD, and pvRSA/HF of loci 1246 
that were genome-wide significant (p<(5x10
-8
)/3) in the analysis of individuals of European 1247 
ancestry.  1248 
Locus Chr SNP 
Position 
(bp) 
(build36) 
Closest 
 Gene 
Annotation Trait 
Allele Stage 1 + 2 
E/O N EAF β(SE) p-value 
1 19 
rs12974991
a
 5845584 
NDUFA11 
IN RMSSD A/G 43205 0.078 -0.116(0.008) 4.57E-46 
rs12974440
a
 5845386 IN pvRSA/HF† A/G 29527 0.073 -0.244(0.019) 1.91E-41 
rs12980262
a
 5844058 M SDNN A/G 46046 0.076 -0.060(0.006) 2.30E-23 
2 12 rs10842383 24663234 
LINC00477 
(C12orf67) 
IG, HR
i
 
SDNN 
C/T 
47808 0.863 -0.049(0.004) 9.33E-31 
RMSSD 43223 0.862 -0.065(0.006) 2.45E-29 
pvRSA/HF† 31085 0.865 -0.124(0.013) 1.20E-25 
3 6 rs236349 36928543 PPIL1 IG 
SDNN 
G/A 
51379 0.651 -0.033(0.003) 3.70E-25 
RMSSD 46795 0.655 -0.035(0.004) 9.10E-17 
pvRSA/HF† 33654 0.645 -0.069(0.009) 3.16E-15 
4 12 
rs7980799
b
 33468257 
SYT10 
IN, HR
ii
 RMSSD A/C 44210 0.390 -0.039(0.004) 3.19E-20 
rs1351682
b
 33490042 IG, HR
iii
 pvRSA/HF† G/A 30643 0.437 -0.073(0.009) 5.70E-15 
rs1384598
b
 33514166 IG, HR
iv
 SDNN T/A 47358 0.432 -0.023(0.003) 7.37E-13 
5 7 
rs4262
c
 93389364 
GNG11 
UTR5, Q, 
HR
v
 
SDNN 
C/T 
49005 0.390 -0.028(0.003) 4.26E-17 
pvRSA/HF† 31281 0.388 -0.050(0.010) 1.84E-11 
rs180238
c
 93388383 UP, Q, HR
vi
 RMSSD C/T 44420 0.333 -0.034(0.004) 7.99E-16 
6 
14b 
rs4899412
d
 71534015 
RGS6 
IN, Q 
SDNN T/C 48252 0.253 -0.026(0.004) 3.13E-13 
rs2052015
d
 71556806 RMSSD T/C 45492 0.165 -0.036(0.006) 3.56E-10 
14c rs2529471 71883022 IN SDNN C/A 49619 0.429 -0.021(0.003) 1.88E-12 
14a rs36423 71422955 IG 
SDNN 
T/G 
48182 0.129 -0.033(0.005) 6.25E-13 
RMSSD 45419 0.127 -0.040(0.006) 5.36E-11 
7 
15a rs2680344 71440538 HCN4 IN, HR
vii
 SDNN A/G 51370 0.777 -0.024(0.004) 4.88E-11 
15b rs1812835 71294557 NEO1 IN, Q RMSSD A/C 44421 0.418 -0.025(0.004) 5.18E-10 
8 20 rs6123471 36273570 KIAA1755 UTR3, HR
viii
 RMSSD T/C 46789 0.534 -0.024(0.004) 1.30E-08 
NOTE: Only SNPs that were independently associated (i.e. lead SNPs) to the traits are shown. At 1249 
some loci lead SNPs were the same for the different traits, at other loci there were different 1250 
(dependent) lead SNPs for the different traits. SNPs are sorted according to p-value of the combined 1251 
meta-analysis per locus. Genome-wide significant association (two-sided p<5x10
-8
), corrected for 1252 
testing three traits (i.e. p<5x10
-8
/3), is shown in bold. Effect alleles were chosen to reflect an 1253 
increased risk for low levels of HRV, hence β's are all negative. 1254 
Chr: chromosome; bp: base pair position based on build 36 (hg18); EAF: effect allele frequency; 1255 
Allele E/O: effect allele/other allele; β: effect size; SE: standard error of β; N: sample size; IN: 1256 
intronic variant; M: missense variant; IG: intergenic variant; UP: upstream variant (within 2kb); 1257 
UTR5: variant in the 5' untranslated region; UTR3: variant in the 3' untranslated region; Q: 1258 
associated with an eQTL; HR: HRV SNPs that are in pairwise LD (based on SNAP, HapMap 1259 
release 22 CEU) with identified loci associated with heart rate (HR) from den Hoed et al. (2013): 
i
 1260 
r
2
=1 between rs10842383 and rs17287293[HR]; 
ii
 same SNP; 
iii
r
2
=0.782 between rs1351682 and 1261 
rs7980799[HR]; 
iv
 r
2
=0.695 between rs1384598 and rs7980799[HR]; 
v
 r
2
=0.570 between rs4262 1262 
and rs180242[HR]; 
vi
 r
2
=0.893 betweenrs180238 and rs180242[HR]; 
vii 
r
2
=0.505 between 1263 
rs2680344 and rs4489968[HR]; 
viii 
r
2
=1 between rs6123471 and rs6127471[HR]; 1264 
a
 these SNPs are all in perfect LD (r
2
=1); 
b
 r
2
=0.782 between rs7980799 and rs1351682; r
2
=0.695 1265 
between rs7980799 and rs1384598; r
2
=0.903 between rs1351682 and rs1384598; 
c
 r
2
=0.600 1266 
between rs4262 and rs180238; 
d
 r
2
=0.237 between rs4899412 and rs2052015;  1267 
†p-value, allele, EAF, N from p-value weighted meta-analysis of all cohorts using METAL and β, 1268 
SE from inverse-variance meta-analysis of only HF cohorts using GWAMA. 1269 
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Table 2: Explained variance in HRV traits in the Lifelines (n=12,101), NESDA (n=2,118), 1270 
TRAILS-Pop (n=1,191), and ABCD (n=1,094) cohorts by the weighted multi-SNP genetic risk 1271 
score based on the independent genome-wide significant SNPs in the stage 1+2 meta-analysis. 1272 
 1273 
    Lifelines   NESDA   TRAILS-Pop   ABCD 
trait risk score 
N 
SNPs p-value ΔR
2
   
N 
SNPs p-value ΔR
2
   
N 
SNPs p-value ΔR
2
   
N 
SNPs p-value ΔR
2
 
SDNN SDNN 9 6.3E-33 1.00%   9 4.9E-10 1.39%   10 8.0E-05 1.28%   10 7.8E-04 1.03% 
SDNN RMSSD 7 1.1E-30 0.93% 
 
11 7.5E-10 1.35% 
 
11 6.3E-06 1.69% 
 
11 3.5E-05 1.56% 
SDNN pvRSA/HF 5 6.4E-25 0.75% 
 
5 5.2E-07 0.89% 
 
5 8.7E-07 1.99% 
 
4 4.3E-03 0.75% 
                 RMSSD SDNN 9 8.3E-37 1.13% 
 
9 2.0E-11 1.54% 
 
10 4.4E-06 1.73% 
 
10 4.7E-04 1.11% 
RMSSD RMSSD 7 8.8E-37 1.13%   11 6.1E-12 1.62%   11 5.3E-08 2.42%   11 2.5E-06 2.01% 
RMSSD pvRSA/HF 5 1.5E-30 0.93% 
 
5 2.0E-11 1.54% 
 
5 2.1E-09 2.92% 
 
4 8.1E-04 1.02% 
                 pvRSA/HF SDNN 7 n.a. n.a. 
 
9 1.5E-13 1.58% 
 
10 4.3E-05 1.38% 
 
10 2.0E-03 0.87% 
pvRSA/HF RMSSD 6 n.a. n.a. 
 
11 7.1E-14 1.62% 
 
11 1.3E-06 1.93% 
 
11 1.5E-05 1.70% 
pvRSA/HF pvRSA/HF 5 n.a. n.a. 
 
5 7.7E-17 2.01% 
 
5 1.4E-08 2.64% 
 
4 1.8E-03 0.89% 
NOTE: ΔR2 is the difference in percentage of explained variance by the multi-SNP genetic or 1274 
polygenic risk score between the models with and without the risk score while adjusting both for 1275 
age, sex, and principal components. 1276 
For Lifelines, NESDA, and TRAILS-Pop the weights (i.e. effects sizes) and number of genome-1277 
wide significant SNPs included in the risk score were adjusted by analytically extracting the 1278 
cohort's effect size and standard error from the meta effect size and standard error, respectively, and 1279 
recalculating the p-value based on these adjusted effect sizes and standard errors, since these 1280 
cohorts were included in stage 1 and/or 2. 1281 
n.a.=not available. 1282 
 1283 
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Table 3: Explained variance in HRV traits in the Lifelines (n=12,101), NESDA (n=2,118), 1284 
TRAILS-Pop (n=1,191), and ABCD (n=1,094) cohorts by the optimal polygenic risk scores 1285 
computed at the p-value threshold that explained the largest percentage of phenotypic variance. 1286 
 1287 
trait risk score cohort p cutoff N SNPs p-value ΔR
2
 
SDNN SDNN Lifelines <5E-7 13 6.8E-27 0.82% 
  NESDA <5E-8 6 2.6E-08 1.16% 
  TRAILS-Pop <5E-5 64 1.1E-04 1.23% 
  ABCD <5E-5 71 9.4E-05 1.39% 
SDNN RMSSD Lifelines <5E-8 8 2.4E-23 0.71% 
  NESDA <5E-6 23 1.2E-07 1.05% 
  TRAILS-Pop <5E-8 8 1.2E-04 1.23% 
  ABCD <5E-7 13 2.8E-06 2.00% 
SDNN pvRSA/HF Lifelines <5E-8 7 3.1E-19 0.58% 
  NESDA <5E-8 4 3.5E-05 0.64% 
  TRAILS-Pop <5E-7 6 9.7E-06 1.61% 
  ABCD <5E-5 67 9.2E-04 1.01% 
RMSSD SDNN Lifelines <5E-7 13 8.9E-31 0.95% 
  NESDA <5E-8 6 1.6E-10 1.46% 
  TRAILS-Pop <5E-8 7 8.3E-06 1.63% 
  ABCD <5E-5 71 1.6E-04 1.30% 
RMSSD RMSSD Lifelines <5E-7 12 2.8E-30 0.94% 
  NESDA <5E-7 10 2.7E-10 1.43% 
  TRAILS-Pop <5E-7 11 3.4E-07 2.13% 
  ABCD <5E-7 13 3.8E-07 2.34% 
RMSSD pvRSA/HF Lifelines <5E-8 7 1.4E-25 0.78% 
  NESDA <5E-8 4 3.6E-09 1.25% 
  TRAILS-Pop <5E-7 6 3.7E-08 2.47% 
  ABCD <5E-8 67 8.4E-04 1.02% 
pvRSA/HF SDNN NESDA <5E-8 6 1.1E-12 1.52% 
  TRAILS-Pop <5E-8 7 5.0E-05 1.36% 
  ABCD <5E-5 71 5.4E-04 1.09% 
pvRSA/HF RMSSD NESDA <5E-7 10 5.6E-14 1.69% 
  TRAILS-Pop <5E-7 11 3.3E-06 1.78% 
  ABCD <5E-7 13 1.9E-06 2.06% 
pvRSA/HF pvRSA/HF NESDA <5E-8 4 4.4E-13 1.58% 
  TRAILS-Pop <5E-7 6 1.6E-07 2.25% 
  ABCD <5E-5 67 1.6E-03 0.90% 
NOTE: Weighted polygenic risk score were determined based on independent SNPs in the stage 1 1288 
meta-analysis. For NESDA and TRAILS-Pop the weights (i.e. effects sizes) and p-values were 1289 
adjusted by analytically extracting the cohort's effect size and standard error from the meta effect 1290 
size and standard error, respectively, and recalculating the p-value based on these adjusted effect 1291 
size and standard error, since these cohorts were included in stage 1. 1292 
n.a.=not available. 1293 
 1294 
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Table 4: Meta-analysis results for the identified loci in other ethnicities and combined meta-1295 
analysis results with European ancestry.  1296 
Locus Chr SNP Trait 
Allele Hispanic/Latino 
 
African American 
 
EUR+HIS+AfAm 
E/O N EAF β (SE) p-value 
 
N EAF β (SE) p-value 
 
p-value 
1 19 
rs12974991 RMSSD A/G 11233 0.065 
-0.162 
(0.018) 
7.05E-20 
 
6673 0.455 
-0.077 
(0.033) 
1.10E-02 
 
1.86E-63 
rs12974440 pvRSA/HF† A/G 404 0.048 
-0.518 
(0.174) 
3.06E-03 
 
1900 0.019 
-0.189 
(0.158) 
3.41E-01 
 
4.53E-41 
rs12980262 SDNN A/G 11233 0.048 
-0.161 
(0.070) 
1.04E-02 
 
6675 0.093 
-0.046 
(0.030) 
6.48E-02 
 
1.57E-24 
2 12 rs10842383 
SDNN 
C/T 
11233 0.854 
-0.053 
(0.012) 
2.45E-06 
 
6676 0.955 
0.056 
(0.026) 
9.83E-01 
 
7.61E-33 
RMSSD 11233 0.854 
-0.064 
(0.012) 
1.38E-07 
 
6673 0.955 
0.065 
(0.030) 
9.86E-01 
 
4.23E-32 
pvRSA/HF† 404 0.830 
-0.140 
(0.095) 
1.40E-01 
 
1901 0.959 
0.068 
(0.104) 
6.79E-01 
 
4.98E-25 
3 6 rs236349 
SDNN 
G/A 
11234 0.684 
-0.034 
(0.009) 
6.15E-05 
 
6676 0.724 
-0.017 
(0.011) 
6.57E-02 
 
1.76E-28 
RMSSD 11234 0.684 
-0.034 
(0.009) 
1.67E-04 
 
6673 0.724 
-0.021 
(0.013) 
4.79E-02 
 
5.88E-20 
pvRSA/HF† 404 0.704 
-0.164 
(0.080) 
4.13E-02 
 
1901 0.729 
0.004 
(0.043) 
4.87E-01 
 
4.64E-15 
4 12 
rs7980799 RMSSD A/C 11234 0.269 
-0.031 
(0.010) 
1.23E-03 
 
6488 0.097 
-0.029 
(0.021) 
7.70E-02 
 
1.57E-22 
rs1351682 pvRSA/HF† G/A 404 0.348 
-0.166 
(0.077) 
3.19E-02 
 
1901 0.142 
-0.082 
(0.058) 
6.91E-02 
 
2.00E-14 
rs1384598 SDNN T/A 11234 0.307 
-0.026 
(0.009) 
1.80E-03 
 
6676 0.146 
-0.024 
(0.015) 
5.41E-02 
 
2.88E-15 
5 7 
rs4262 
SDNN 
C/T 
11234 0.427 
-0.016 
(0.008) 
2.39E-02 
 
6676 0.608 
-0.028 
(0.011) 
5.87E-03 
 
5.36E-19 
pvRSA/HF† 404 0.410 
-0.014 
(0.074) 
8.46E-01 
 
1901 0.618 
-0.055 
(0.043) 
1.15E-01 
 
1.50E-11 
rs180238 RMSSD C/T 11234 0.367 
-0.024 
(0.009) 
4.05E-03 
 
6673 0.474 
-0.032 
(0.011) 
2.77E-03 
 
8.07E-19 
6 
14b 
rs4899412 SDNN T/C 11234 0.329 
-0.012 
(0.009) 
8.27E-02 
 
6676 0.419 
-0.009 
(0.010) 
1.86E-01 
 
5.96E-13 
rs2052015 RMSSD T/C 11234 0.173 
-0.015 
(0.012) 
9.94E-02 
 
6673 0.098 
-0.001 
(0.020) 
4.83E-01 
 
1.94E-09 
14c rs2529471 SDNN C/A 11233 0.485 
-0.018 
(0.008) 
1.38E-02 
 
6676 0.543 
0.003 
(0.010) 
3.83E-01 
 
2.08E-12 
14a rs36423 
SDNN 
T/G 
11234 0.193 
-0.021 
(0.011) 
2.41E-02 
 
6676 0.160 
-0.030 
(0.015) 
1.79E-02 
 
1.60E-14 
RMSSD 11234 0.193 
-0.017 
(0.011) 
7.05E-02 
 
6673 0.160 
-0.034 
(0.016) 
1.72E-02 
 
1.02E-11 
7 
15a rs2680344 SDNN A/G 11234 0.681 
-0.005 
(0.009) 
2.97E-01 
 
6676 0.450 
-0.024 
(0.011) 
1.32E-02 
 
2.90E-11 
15b rs1812835 RMSSD A/C 11234 0.426 
-0.012 
(0.009) 
8.83E-02 
 
1388 0.140 
-0.009 
(0.033) 
3.98E-01 
 
5.30E-10 
8 20 rs6123471 RMSSD+ T/C 11234 0.560 
-0.001 
(0.009) 
4.40E-01 
 
6673 0.739 
0.020 
(0.013) 
5.67E-02 
 
5.14E-06 
NOTE: SNPs sorted as in Table 1 according to the European ancestry combined meta-analysis p-1297 
value per locus. Significant ps are shown in bold (see text for criteria). Effect alleles were chosen to 1298 
reflect an increased risk for low levels of HRV, hence β's are all negative. 1299 
Chr: chromosome; bp: base pair position based on build 36 (hg18); Allele E/O: effect allele/other 1300 
allele; EAF: effect allele frequency; β: beta/effect size; SE: standard error of β; EUR: European; 1301 
HIS: Hispanic/Latino; AfAm: African American.  1302 
†p-value, allele, EAF, N from z-score weighted meta-analysis of all cohorts using METAL and β, 1303 
SE from inverse-variance meta-analysis of only HF cohorts using GWAMA.   1304 
+ β of participants of European ancestry differs significantly from that of participants from African-1305 
American (diff β = 0.044, p =0.0012) or Hispanic/Latino ancestry (diff β = -0.023, p= 0.0195). 1306 
 1307 
